VAPRED Study

D-Dimer Microchapters
Home
Patient information
Overview
Historical Perspective
Physiology
Clinical Correlation
Causes of High D-dimer
Diagnostic Role in Thromboembolism
Prognostic Role in Mortality
Prognostic Role in Thromboembolism Occurence
Prognostic Role in Thromboembolism Recurrence
Prognostic Role in Non-Thromboembolism
Clinical Trials
Landmark Trials
Case #1
VAPRED Study On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of VAPRED Study All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on VAPRED Study
CDC on VAPRED Study
VAPRED Study in the news
Blogs on VAPRED Study
Directions to Hospitals Treating D-dimer
Risk calculators and risk factors for VAPRED Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Official Title

Study of Predictive Echo Doppler Score and D-dimer Level in Evaluation of the Thromboembolic Event Recurrence After Anticoagulant Treatment Cessation

Objective

The purpose of this trial is to perform a prospective multicentric study to determine predictive ED score and D-dimer level in the evaluation of the thromboembolic event recurrence after anticoagulant treatment cessation

Sponsor

University Hospital, Grenoble

Timeline

Timeline
Start Date	March 2005
End Date	May 2010
Status	phase 4

The previous information was derived from ClinicalTrials.gov on 09/20/2013 using the identification number NCT00860106 .

Study Description

Study Description
Study Type	Interventional
Study Phase	Phase 4
Study Design
Allocation	Non-Randomized
Endpoint	Safety Study
Interventional Model	Single Group Assignment
Masking	Open Label
Study Details
Primary Purpose	Prevention
Condition	Previous Vka Treatment Previous Proximal VTE
Intervention	Echo Doppler (ED), DDimers and phone follow up ED score, DDimers level and phone questionnary
Study Arms	Follow up ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE). Phone follow up for 2 years. Intervention: Other: ED, DDimers and phone follow up
Population Size	222

The previous information was derived from ClinicalTrials.gov on 09/20/2013 using the identification number NCT00860106 .

Eligibility Criteria

Inclusion Criteria

• >18 and <80 years old
• First or second treated proximal VTE event (+/- Pulmonary embolism)
• Signed informed consent

Exclusion Criteria

• Active cancer or currently treated
• Previous VTE>2
• Long term anticoagulant treatment for VTE diseases
• Long term anticoagulant treatment for other diseases
• Pregnancy, parturient or breast feeding
• Person deprived of freedom by judicial or administrative decision
• Consent unsigned

Outcomes

Primary Outcomes

VTE event recurrence [ Time Frame: 0-2 years ] [ Designated as safety issue: Yes ]

Secondary Outcomes

Not provided